

ASX Announcement

AdAlta Limited Company Secretary Appointment

MELBOURNE Australia, 31 May, 2017: AdAlta Limited (ASX:1AD), the biotechnology Company advancing its lead i-body candidate towards clinical development, today announced the appointment of Cameron Jones, as Company Secretary effective as at the close of the board meeting held on May 31, 2017 and the resignation of Ian Hobson.

Cameron Jones is a Chartered Accountant and holds a Certificate in Governance (Practice) from the Governance Institute of Australia and will assume responsibility for Australian Securities and Investments (ASIC) reporting, ASX compliance and reporting, planning and execution of annual reporting and shareholder meetings as well as Chief Financial Officer of AdAlta.

Cameron is also a Director of Bio101Group Pty Ltd, a wholly owned subsidiary of Biotech Capital Limited and has previously worked at Pitcher Partners.

Chief Executive Officer Sam Cobb said, “The Board would like to thank Ian for his support and contribution as Company Secretary during AdAlta’s IPO. We are looking forward to Cameron Jones assuming responsibility for AdAlta’s Company secretarial responsibilities.”

Notes to Editors

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: s.cobb@adalta.com.au